• KOL
    • Rheumatoid Arthritis
    • John Turner Sharp
    • John Turner Sharp: Influence Statistics

      John Turner Sharp

      John Turner Sharp

      Show email address

      Maastricht University Medical Center, Department of Internal Medicine, Subdivision of Rheumatology, Maastricht, The Netherlands. | Division of Rheumatology, University of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      John Turner Sharp:Expert Impact

      Concepts for whichJohn Turner Sharphas direct influence:Rheumatoid arthritis,Radiographic progression,Coronary embolism,Thoracoabdominal motion,Respiratory muscle function,Joint space width,Psoriatic arthritis,Monoclonal antibodies.

      John Turner Sharp:KOL impact

      Concepts related to the work of other authors for whichfor which John Turner Sharp has influence:Rheumatoid arthritis,Synovial fluid,Systemic lupus erythematosus,Necrosis factor,Rheumatic diseases,Radiographic progression,Ankylosing spondylitis.

      KOL Resume for John Turner Sharp

      Year
      2009

      Maastricht University Medical Center, Department of Internal Medicine, Subdivision of Rheumatology, Maastricht, The Netherlands.

      Division of Rheumatology, University of Washington, Seattle, Washington, DC, USA

      2008

      University of Washington, Seattle

      2007

      University of Washington, Seattle, Washington, USA

      2005

      University of Washington School of Medicine, Seattle, WA, USA.

      2004

      Department of Medicine, University of Washington School of Medicine, 1959 Northeast Pacific Street, Seattle, WA 98195-6428, USA

      2003

      University of Washington, Seattle, Washington, USA.

      2002

      University of Washington, School of Medicine, Seattle

      2001

      University of Washington, Seattle, WA

      2000

      8387 NE Sumanee Place, Bainbridge Island, WA 98110

      Bainbridge Island, Washington

      1998

      Emory University, Atlanta, Georgia

      1996

      Tifton Medical Center, Tifton, Georgia

      1995

      Tifton Medical Clinic, Tifton, Georgia, and Emory University School of Medicine, Atlanta, Georgia

      1993

      Tifton, Georgia

      Cooperative Systemic Studies of the Rheumatic Diseases group

      1991

      712 East 18th Street, Tifton, GA 31794

      University of Colorado School of Medicine, and Director, The Joe and Betty Alpert Arthritis Center at Rose Medical Center

      1988

      Staff Physician, Tifton Medical Clinic, Tifton, GA

      From the Rheumatoid Arthritis Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association

      1987

      From a conference sponsored, in part, by Sandoz Pharmaceuticals, April 25—28, 1985, San Francisco, CA

      Tifton Medical Clinic, Tifton, Georgia

      1986

      From the Department of Medicine, Pulmonary Disease Section, and the Research Service, Hines Veterans Administration Hospital, Hines, Ill., USA

      Department of Medicine, Joe and Betty Alpert Arthritis Center, Denver, Colorado

      1985

      Alpert Arthritis Center, 4567 East Ninth Avenue, Denver, CO 80220

      Pulmonary Medicine, Hines V.A. Hospital, Hines, IL

      1983

      Professor of Medicine, Loyola Stritch School of Medicine, Maywood, Illinois

      1982

      From the Nuclear Medicine Service, Veterans Administration Hospital, Hines, Ill.

      Rheumatic Disease Section, Department of Internal Medicine, Baylor College of Medicine, Houston, TX and Joe and Betty Alpert Arthritis Treatment Center, Rose Medical Center, Denver, CO

      1981

      Pulmonary Medicine Section, Medical Service, Hines Veterans Administration Hospital, Hines, IL

      Department of Medicine, Abraham Lincoln School of Medicine, University of Illinois College of Medicine, Chicago

      Veterans Administration Hospital, Hines, Illinois, Argonne National Laboratories, Lemont, Illinois, USA

      1980

      Program Director, Pulmonary Medicine, Hines, V. A. Hospital; Professor of Medicine and Physiology, University of Illinois College of Medicine, Chicago, Illinois

      1979

      Section of Pulmonary Medicine, Loyola University of Chicago, Stritch School of Medicine, Maywood, and the Section of Pulmonary Medicine, Veterans Administration Hospital, Hines, Ill

      1977

      Danville Veterans Administration Hospital, Danville, Illinois 61832

      Pulmonary Disease, Veterans Administration Hospital, Hines, Ill

      Rheumatic Disease Section and the Section of Biomedical Computing, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas

      1976

      From the Pulmonary Section, Department of Medicine, Veterans Administration Hospital, Hines, Illinois and the Departments of Physiology and Medicine, University of Illinois, Chicago

      1973

      Professor of Medicine and Chief, Rheumatology Section, Department of Medicine, Baylor College of Medicine

      1972

      Professor, Department of Medicine, Baylor College of Medicine, Houston, Texas 77025

      1971

      Department of Medicine, Baylor College of Medicine, Houston, Texas

      Professor of Medicine, Chief, Rheumatic Disease Section, Baylor College of Medicine, Houston, Tex 77025

      1970

      From the Loyola University Stritch School of Medicine, Hines, Ill. U.S.A.

      Departments of Microbiology and Medicine, Baylor College of Medicine, 77025, Houston, Texas

      1969

      Goroka Hospital, Territory of Papua and New Guinea, Sydney Hospital

      Departments of Medicine and Virology, Baylor College of Medicine, Houston, Texas

      1968

      Chicago, Illinois, USA

      Rheumatic Disease Section, Department of Medicine, Baylor University College of Medicine, the Ben Taub General Hospital, and Houston Veterans Administration Hospital

      1967

      From the Section of Cardiology and the Cardiopulmonary Laboratory, Veterans Administration Hospital and the Department of Medicine, University of Illinois College of Medicine, Hines, Illinois

      1965

      From the Cardiopulmonary Laboratory of the Veterans Administration Hospital, Hines, Ill., USA

      1964

      Cardiopulmonary Laboratory of the Veterans Administration Hospital, Hines, Illinois, and Departments of Medicine of the University of Illinois College of Medicine and Stritch School of Medicine of Loyola University, Chicago, Illinois

      1963

      From the Cardiopulmonary Laboratories of the Veterans Administration Hospital, Hines, Illinois, and the Children's Hospital, Buffalo, New York; the Departments of Medicine of the Stritch School of Medicine, Loyola University, and the University of Illinois College of Medicine; and the Department of Pediatrics, University of Buffalo School of Medicine, Buffalo, New York.

      1961

      This work was carried out during tenure of an Established Investigatorship of the American Heart Association. Dr. Sharp's present address is the Cardiopulmonary Laboratory, Veterans Administration Hospital, Hines, Ill.

      From the Cardiopulmonary Laboratory, Veterans Administration Hospital, Hines, Illinois, the Department of Medicine, Stritch School of Medicine of Loyola University, the Department of Radiology, the University of Chicago School of Medicine, and the Department of Medicine, University of Illinois School of Medicine, Chicago, Illinois.

      1960

      Buffalo, New York USA

      1959

      Established Investigator of the American Heart Association and Buswell Fellow in Medicine.

      1958

      Established Investigator of the American Heart Association.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which John Turner Sharp is among the top experts in the world.
      Concept World rank
      20 cell strains #1
      classifying structural #1
      antigens initiation #1
      hypotonia orofacial muscles #1
      rheumatoid arthritis multicenter #1
      emg lung #1
      synovial membrane nonrheumatoid #1
      atrium venae cavae #1
      electromyography heart humans #1
      chemical streptokinase trichophyton #1
      arthritis observed #1
      thirtyone months #1
      obesity oxygen respiration #1
      matched controls measles #1
      healthy patients patient #1
      emg lung volume #1
      sequence radiographs #1
      dyedilution studies #1
      dirhythmic breathing patients #1
      synovialvero #1
      extremes cycles #1
      antivascular antibody #1
      lymphocyte proliferation initiation #1
      new computerbased methods #1
      possibility lymphocytes #1
      disease erosions #1
      early seropositive association #1
      placebo denosumab doses #1
      skin reactivity decrease #1
      shunt dyedilution studies #1
      bronchospasm theclock #1
      biweekly monthly intervals #1
      obesity electromyography #1
      fever dermatologic #1
      prevents metacarpal #1
      erosion scores patients #1
      goodpastures syndrome cyclophosphamide #1
      190 patients early #1
      81mkr regional ventilation #1
      Sign-in to see all concepts, it's free!

      Prominent publications by John Turner Sharp

      KOL-Index: 25920

      OBJECTIVE: Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular matrix degradation in rheumatoid arthritis (RA). We investigated the ability of adalimumab, a human anti-TNF monoclonal antibody, to inhibit the progression of structural joint damage, reduce the signs and symptoms, and improve physical function in patients with active RA receiving concomitant treatment with methotrexate (MTX).

      METHODS: In this multicenter, ...

      Known for Adalimumab Patients | Active Rheumatoid | Physical Function | Arthritis Receiving | Factor Monoclonal
      KOL-Index: 22236

      OBJECTIVE: To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment.

      METHODS: This was a 2-year, multicenter, double-blind, active comparator-controlled study of 799 RA patients with active disease of < 3 years' duration who had never been treated with MTX. Treatments included adalimumab 40 mg subcutaneously every ...

      Known for Combination Therapy | Adalimumab Mtx | Clinical Trial | Methotrexate Treatment | Premier Study
      KOL-Index: 18438

      OBJECTIVE: To evaluate the efficacy and safety of treatment with adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, over 48 weeks in patients with moderate to severe psoriatic arthritis (PsA).

      METHODS: Patients who completed the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT), a 24-week, double-blind study of adalimumab versus placebo in PsA, could elect to receive open-label adalimumab, 40 mg subcutaneously every other week after week 24. ...

      Known for Adalimumab Effectiveness | Psoriatic Arthritis | Week Patients | Monoclonal Antibodies
      KOL-Index: 15867

      OBJECTIVE: To determine the relationship between radiographic progression and clinical response for adalimumab plus methotrexate (MTX) versus either monotherapy in patients with early rheumatoid arthritis (RA) in the PREMIER study.

      METHODS: Patients with early RA who received adalimumab plus MTX (n = 240), adalimumab (n = 222), or MTX (n = 216) were grouped by American College of Rheumatology (ACR) response, 28-joint Disease Activity Score (DAS28), or remission-like state [tender joint ...

      Known for Radiographic Progression | Methotrexate Monotherapy | Mtx Adalimumab | Monoclonal Antibodies | Rheumatoid Arthritis
      KOL-Index: 15770

      OBJECTIVE: Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA).

      METHODS: Patients with moderately to severely active PsA and a history of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg adalimumab or placebo subcutaneously every other week for 24 weeks. Study visits were at baseline, weeks 2 and 4, and ...

      Known for Adalimumab Placebo | Humanized Arthritis | Quality Life | Patients Monoclonal Antibodies | 24 Weeks
      KOL-Index: 15522

      OBJECTIVE: Three 6-12-month, double-blind, randomized, controlled trials have shown leflunomide (LEF; 20 mg/day, loading dose 100 mg x 3 days) to be effective and safe for the treatment of rheumatoid arthritis (RA). This analysis of the North American trial assessed whether the clinical benefit evident at month 12 was sustained over 24 months of treatment with LEF as compared with the efficacy and safety of methotrexate (MTX), an equivalent disease-modifying antirheumatic drug, at 24 ...

      Known for Lef Mtx | 24 Months | Rheumatoid Arthritis | Year Treatment | Radiographic Progression
      KOL-Index: 15417

      OBJECTIVE: To determine whether treatment with leflunomide (LEF), methotrexate (MTX), or sulfasalazine (SSZ) for 6-12 months retards progression of radiographic damage and to identify clinical variables that correlate with radiographic progression.

      METHODS: Radiographs of the hands and feet were performed at baseline and at the end of study or early exit in 3 randomized controlled trials. Protocol US301 was a 12-month controlled trial of LEF or MTX treatment compared with placebo in 482 ...

      Known for Radiographic Progression | Lef Mtx | Rheumatoid Arthritis | Randomized Controlled | 12 Months
      KOL-Index: 15182

      OBJECTIVE: RANKL is essential for osteoclast development, activation, and survival. Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting its activity. The aim of this multicenter, randomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment.

      METHODS: RA patients received subcutaneous placebo (n = 75), denosumab 60 mg (n = ...

      Known for Structural Damage | Bone Turnover | Rheumatoid Arthritis | Placebo Denosumab | Monoclonal Antibodies
      KOL-Index: 13016

      OBJECTIVE: Etanercept has been shown to improve the articular and cutaneous manifestations of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA.

      METHODS: Patients with PsA (n = 205) were randomized to receive placebo or 25 mg etanercept subcutaneously twice weekly for 24 weeks. Patients continued to receive blind-labeled therapy in a maintenance phase until all had completed the ...

      Known for Etanercept Treatment | Psoriatic Arthritis | 24 Weeks | Efficacy Safety | Placebo Patients
      KOL-Index: 12833

      OBJECTIVE: To evaluate the long-term effectiveness and tolerability of adalimumab in the treatment of psoriatic arthritis (PsA).

      METHODS: Patients with PsA who completed a 24-week, double-blind study of adalimumab versus placebo were eligible to enroll in an open-label extension study and receive adalimumab 40 mg subcutaneously every other week for up to an additional 120 weeks. At the time of this analysis, available efficacy evaluations throughout 2 years of treatment (n = 245) ...

      Known for Psoriatic Arthritis | Adalimumab Treatment | Monoclonal Antibodies | Patients Psa | Joint Disease
      KOL-Index: 11319

      OBJECTIVE: Joint damage is related to disease activity in rheumatoid arthritis (RA), but the degree of its progression and the temporal associations between disease activity and joint damage are unclear. The aim of this study was to evaluate whether there is a latency in the effect of disease activity on radiographic progression in patients with RA.

      METHODS: Data were obtained from the PREMIER trial, a 2-year randomized, controlled clinical trial of adalimumab plus methotrexate versus ...

      Known for Radiographic Progression | Sustained Remission | Rheumatoid Arthritis | Monoclonal Antibodies | Year Patients
      KOL-Index: 10793

      OBJECTIVE: To evaluate published proposed definitions of minimal disease activity (MDA) and remission in patients with early rheumatoid arthritis (RA).

      METHODS: The cohort comprised disease-modifying antirheumatic drug (DMARD)-naive patients with early seropositive active RA (n = 200) treated with traditional DMARDs in the prebiologic era. MDA definitions included Disease Activity Score in 28 joints (DAS28)

      Known for Minimal Disease Activity | Arthritis Cohort | Mda Das28 | Remission Patients | Illness Terminology
      KOL-Index: 10398

      OBJECTIVE: This study was conducted 1) to determine the feasibility of using computer programs to measure radiographic joint space width and estimate erosion volume in the hands of patients with rheumatoid arthritis (RA), and 2) to compare the new computer-based methods with established scoring methods.

      METHODS: To measure the joint space width in the finger and wrist joints of RA patients, hand and wrist radiographic films were scanned using a tabletop scanner and analyzed with programs ...

      Known for Erosion Volume | Joint Space | Rheumatoid Arthritis | Scoring Methods | Computer Assisted

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      #1
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      #2
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      #3
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      #4
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      #5
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      #6
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Maastricht University Medical Center, Department of Internal Medicine, Subdivision of Rheumatology, Maastricht, The Netherlands. | Division of Rheumatology, University of Washington, Seattle, Washington, DC, USA | University of Washington, Seattle |

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.